Introduction: Renal cell carcinoma (RCC) with sarcomatoid component carries a poor prognosis. Immune checkpoint inhibitors (CPIs) have been approved for the treatment of metastatic RCC, but their efficacy in patients with sarcomatoid component is not known. Materials and Methods: We conducted a retrospective chart review of 30 consecutive patients at our center who were treated for metastatic RCC with sarcomatoid component. Results: Ten patients were treated with CPI group while 20 patients were in No-CPI group. There were no significant differences in age, sex, race, and stage at diagnosis between the two groups. After a median follow-up of 35 months, 3 of 10 patients in CPI arm and 5 of 20 patients in No-CPI group were alive. The median overall survival was 33.8 m in immunotherapy group compared to 8.8 m in nonimmunotherapy group (p = .001). Discussion: In our experience, CPI therapy resulted in better outcomes compared to traditional therapy with molecular-targeted agents or chemotherapy in these patients.
Oncoimmunology. 2019 Apr 25*** epublish ***
Ahmad Hanif, Manu Pandey, Sumera Khan, Kristopher Attwood, Saby George
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.